Elanco Animal Health Incorporated (NYSE:ELAN) just released its latest first-quarter results and things are looking bullish. It was overall a positive result, with revenues beating expectations by 7.5% to hit US$1.4b. Elanco Animal Health reported statutory earnings per share (EPS) US$0.11, which was a notable 15% above what the analysts had forecast. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Taking into account the latest results, the consensus forecast from Elanco Animal Health's 14 analysts is for revenues of US$5.04b in 2026. This reflects a modest 3.0% improvement in revenue compared to the last 12 months. Elanco Animal Health is also expected to turn profitable, with statutory earnings of US$0.15 per share. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$5.00b and earnings per share (EPS) of US$0.089 in 2026. There was no real change to the revenue estimates, but the analysts do seem more bullish on earnings, given the considerable lift to earnings per share expectations following these results.

The consensus price target was unchanged at US$29.86, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Elanco Animal Health, with the most bullish analyst valuing it at US$32.00 and the most bearish at US$24.00 per share. This is a very narrow spread of estimates, implying either that Elanco Animal Health is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Elanco Animal Health's rate of growth is expected to accelerate meaningfully, with the forecast 4.0% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 0.6% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 8.8% per year. So it's clear that despite the acceleration in growth, Elanco Animal Health is expected to grow meaningfully slower than the industry average.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Elanco Animal Health following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Elanco Animal Health going out to 2028, and you can see them free on our platform here.

It might also be worth considering whether Elanco Animal Health's debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.